Shionogi banks on Crestor for first-quarter growth
This article was originally published in Scrip
Executive Summary
A continued rise in royalties deriving from AstraZeneca's global sales of Crestor (rosuvastatin) again helped Japanese company Shionogi weather domestic sales declines for many of its major products in the first quarter to June 30th.